CADL Stock Analysis: Buy, Sell, or Hold?
CADL - Candel Therapeutics, Inc. Common Stock
$9.64
0.15 (1.58%)
▲
5d:
-3.89%
30d:
+15.45%
90d:
+99.59%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
29d
Get Alerted When CADL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
6 traders called CADL this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CADL shows positive signals but monitor for confirmation. Market pricing in 2.9% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CADL shows positive signals but monitor for confirmation. Market pricing in 2.9% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.71
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.79
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CADL is currently trading at $9.64, which is considered slightly high relative to its 30-day fair value range of $8.45 to $9.91. The stock's valuation (Forward PE: 43.8) is in line with its historical norms (40.2). At these levels, the market is pricing in 2.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $9.19, while resistance sits at $11.36.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.29 (+110.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $9.19, while resistance sits at $11.36.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.29 (+110.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.45 -
$9.91
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 110.4% below Wall St target ($20.29)
- NEUTRAL: Market pricing in 2.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$8.45 -
$9.91
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$9.19
Resistance Level
$11.36
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.82
Wall Street Target
$20.29
(+110.4%)
Valuation Premium vs History
+2.9% premium
PE vs Historical
43.8 vs 40.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.9%
(market-implied from PE analysis)
1-Year Target
$9.92
(+3%)
2-Year Target
$10.21
(+6%)
3-Year Target
$10.50
(+9%)
3-Yr Target (if PE normalizes)
(PE: 44→40)
PE COMPRESSION
$9.64
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 14, 2026 12:34 AM ET
Data refreshes hourly during market hours. Next update: 1:34 AM
Data refreshes hourly during market hours. Next update: 1:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CADL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Paul B Manning
BUY
550458 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 61 BUY |
